# Polar Capital

> Polar Capital is a VC fund in London backing Biotechnology and Pharmaceutical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 11
- Last investment: Mar 2026
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/polar-capital-partners/
- Website: http://www.polarcapital.co.uk

Polar Capital is a specialist investment management company offering professional and institutional investors a range of geographical and sector funds.

## Contacts

5 contacts available for Polar Capital. Shizune tracks 4 team members at Polar Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/polar-capital-holdings?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Pharmaceutical | 4 | 36% |
| Therapeutics | 3 | 27% |
| Banking | 2 | 18% |
| FinTech | 2 | 18% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 7 | 64% |
| Series A | 1 | 9% |
| Series D | 1 | 9% |
| Funding Round | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 36% |
| United States | 3 | 27% |
| France | 2 | 18% |
| Sweden | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gavin Rochussen | CEO | 0 | — |
| Nick Martin | Fund Manager | 0 | — |
| John Mansell | CFO | 0 | — |
| Tim Woolley | Co-Founder | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MedinCell | MedinCell is an injectable slow-release drug specialist company. | $55.7M | Post-IPO Equity | Mar 05, 2026 |  |
| Hansa Biopharma | Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic ordisease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications. | $71M | Post-IPO Equity | Oct 02, 2025 |  |
| MedinCell | MedinCell is an injectable slow-release drug specialist company. | $44.7M | Post-IPO Equity | Feb 19, 2025 |  |
| Valneva | Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $67.8M | Post-IPO Equity | Sep 13, 2024 |  |
| Spyre Therapeutics | Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies with the potential to revolutionize the treatment of inflammatory bowel disease (IBD). | $180M | Post-IPO Equity | Dec 07, 2023 |  |
| New Level Work | BetterManager provides leadership coaching and development programs for managers. They provide a proven, tech-enabled solution that has worked for some of the largest, most successful organizations out there. Founded in 2017, the firm has its headquarters in San Francisco, California, United States. | $16M | Series A | Nov 18, 2022 |  |
| Moneybox | Moneybox is a user-friendly app designed to help individuals save, invest, and manage pensions with ease. The app allows users to save specifically for their first home, making it an excellent choice for first-time buyers. The company focuses on helping individuals build wealth over time by offering a variety of financial services, including savingaccounts, investment products, and pensions, all accessible through a mobile app. | $45.9M | Series D | Apr 04, 2022 |  |
| Verona Pharma | Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. | $200M | Post-IPO Equity | Jul 17, 2020 |  |
| Realm Therapeutics | Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseaseswith potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases. | $26M | Post-IPO Equity | Sep 22, 2017 |  |
| Plant Impact | Their products manage a plant’s natural responses to stress factors to build its resilience. This boost in strength helps the plant to flourish in good conditions but also when faced with increasingly common stresses such as heat, salinity, drought and the application of other chemicals.Their head office and primary research facility are at theRothamsted Centre for Research and Enterprise (RoCRE) in Harpenden, UK and they have additional offices in Brazil, USA and Argentina as well as colleagues based in Turkey and France. | $5.1M | Post-IPO Equity | Aug 23, 2017 |  |

10 of 11 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology) — VC Fund, 2 deals together
- Affinity Asset Advisors — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together
- [Fairmount Funds Management](https://shizune.co/investors/profile/fairmount-funds-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Polar Capital invest in?

Polar Capital invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Polar Capital?

Public channels for Polar Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Polar Capital?

The team at Polar Capital includes Gavin Rochussen (CEO), Nick Martin (Fund Manager) and John Mansell (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co